Skip to ContentSkip to Navigation
About us Practical matters How to find us dr. S.W.M. (Sophia) Bruggeman

Research interests

Telephone:
+31 503619554
E-mail: s.w.m.bruggeman@umcg.nl
 

Curriculum Vitae

Sophia Bruggeman (The Netherlands, 1979) studied Biology at the University of Nijmegen. As PhD student, she worked at the Netherlands Cancer Institute on the role of Polycomb group genes in brain development and cancer (2008, cum laude). She next moved to King's College London to work on the development of the chick and zebrafish forebrain on a KWF postdoctoral fellowship. This fellowship was completed at the European Research Institute for the Biology of Ageing (ERIBA/University Medical Center Groningen).

After awardance of a Rosalind Franklin fellowship (tenure track position) and a KWF Cancer Research career award, Sophia started her own research group at the department of Pediatric Oncology and Hematology/Pediatrics, UMCG (2014). In 2019, Sophia's research group moved to ERIBA, UMCG. Her research aims at understaning how normal neurodevelopmental processes influence pediatric brain cancer initiation and progression.

Publications

Targeting the reprogrammed metabolism in H3.3K27M pediatric high-grade gliomas

Chromosomal Instability Characterizes Pediatric Medulloblastoma but Is Not Tolerated in the Developing Cerebellum

The developmental stage of the medulloblastoma cell-of-origin restricts Hedgehog pathway usage and drug sensitivity

CREB signaling activity correlates with differentiation and survival in medulloblastoma

Heat Shock Factor 1 (HSF1-pSer326) Predicts Response to Bortezomib-Containing Chemotherapy in Pediatric AML: A COG Study

The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma

Loss of H3K27 Methylation Identifies Poor Outcome in Adult-Onset Acute Myeloid Leukemia

Loss of H3K27 Methylation Identifies Poor Outcomes in Adult-Onset Acute Lymphoblastic and Myeloid Leukemia

Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

The developmental stage of the medulloblastoma cell-of-origin is maintained in cancer and restricts hedgehog pathway usage and drug sensitivity

Read more